Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous magnesium sulfate for rapid ventricular rate control in atrial fibrillation
ACTRN12619000532101Phase 4Recruiting
- Sponsor
- Eastern Health Foundation
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of magnesium sulfate in Atrial fibrillation (AFib) (2 arms), sponsored by Eastern Health Foundation. Primary endpoint: Primary outcome: heart rate reduction at 1 hour. Started Apr 2019; status: recruiting.
02
Drugs
magnesium sulfate
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ACTRN12619000532101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000532101.